

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Zhou, et al.
Serial No: Not Yet Assigned
Filed: Herewith
For: NOVEL NUCLEIC ACIDS AND
POLYPEPTIDES


CERTIFICATE OF MAILING
BY "EXPRESS MAIL" UNDER 37 CFR § 1.10

"Express Mail" Mailing Label Numbers
EL933683678US

Date of Deposit: January 4, 2002

I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Arlington, VA 22202.

Type or Print Name of Person Mailing: Petrina S. Hsi



Signature of Person Mailing

PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office
Arlington, VA 22202
Attn: BOX PATENT APPLICATION

Dear Sir:

Prior to substantive examination, please amend the application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

At page 1, in the Cross Reference to Related Applications, please insert the following sentence after the title: -- This is a divisional of U.S. Application Serial No. 09/620,312, filed July 19, 2000, entitled "Novel Nucleic Acids and Polypeptides", Attorney Docket No. 784CIP2B.--

IN THE CLAIMS

Please cancel claims 1-9, 12-19 and 21-28.

Kindly replace pending claims 10 and 20 with the following claims:

10. An isolated polypeptide encoded by the polynucleotide of SEQ ID NO: 482.
20. An isolated polypeptide encoded by the polynucleotide comprising a nucleic acid sequence which is 99% identical to the nucleic acid sequence of SEQ ID NO: 482.

REMARKS

Upon entry of the foregoing amendments, claims 10, 11, 20 and 21 are under consideration.

Support for the amendment to claim 10 appears at least in the originally filed claim 10. Support for the amendment to claim 21 appears at least at page 30, line 15 of the specification. Thus, these amendments add no new matter.

CONCLUSION

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in a condition for allowance. The undersigned can be reached at 408-746-4536 if the Examiner wishes to discuss the response.

An early action on the merits is respectfully requested.

Respectfully submitted,

Date: January 4, 2002

By: Luisa Bigornia
Luisa Bigornia
Attorney for Applicants
Registration No.: # 45,974
HYSEQ, INC.
670 Almanor Avenue
Sunnyvale, CA 94085
(408) 524-8100
(408) 524-8145 (Telefacsimile)

Version With Markings to Show Changes

In the Specification:

The specification was amended as follows:

1. CROSS REFERENCE TO RELATED APPLICATIONS

This is a divisional of U.S. Application Serial No. 09/620,312, filed July 19, 2000,
entitled "Novel Nucleic Acids and Polypeptides", Attorney Docket No. 784CIP2B. This
application is a continuation-in-part of U.S. Application Serial No. 09/552, 317, filed April 25,
2000, which in turn is a continuation-in-part application of U.S. Application Serial No.
09/488,725, filed January 21, 2000, both of which are incorporated herein by reference in their
entirety.

In the Claims:

Claims 1-9, 12-19 and 22-28 were canceled.

Claims 10 and 20 have been amended as follows:

10. (amended) An isolated polypeptide, [wherein the polypeptide is selected from the group
consisting of :

(a) a polypeptide] encoded by SEQ ID No: 482 [any one of the polynucleotides of
claim 1; and

(b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions
with any one of SEQ ID NO: 1-877, 879-1104].

20. (amended) An isolated polypeptide [comprising the amino acid sequence selected from
the group consisting of any one of the polypeptides from the Sequence Listing, the mature
protein portion thereof, or the active domain thereof] encoded by the polynucleotide comprising a
nucleic acid sequence which is 99% identical to the nucleic acid sequence of SEQ ID NO: 482.